

Ref. No: 276100921
From: Commercial
Date: 10/09/21
Subject: Biologics drugs

REQUEST

I have a FOI request related to the usage of Biologic drugs.

A. Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Filgotinib
- Golimumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Tofacitinib
- Ustekinumab
- Vedolizumab

B. How many patients were treated in the last 3 months for Crohn's Disease ONLY with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Golimumab
- Infliximab - Remicade
- Infliximab Biosimilars
- Ustekinumab
- Vedolizumab

RESPONSE

A. Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

Number of Gastroenterology patients issued between 1st June 2021 to 31st August 2021:

	Number of Patients
Adalimumab - Humira	*<5
Adalimumab Biosimilar	83
Filgotinib	0
Golimumab	*<5
Infliximab - Remicade	0
Infliximab Biosimilar	110
Tofacitinib	*<5
Ustekinumab	57
Vedolizumab	59

* **Please note:** We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018. In such circumstances sections 40(2) and (3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle. This states that personal data should be processed “lawfully, fairly and in a transparent manner”. It is the lawful aspect of this principle which, in our view, would be breached by disclosure. In such circumstances section 40 confers an absolute exemption on disclosure.

B. How many patients were treated in the last 3 months for Crohn’s Disease ONLY with the following biologic drugs:

Pharmacy systems do not record the indication being treated and are therefore unable to answer this part.